8-K: Dogwood Therapeutics Launches $8.5M At-The-Market Offering

Dogwood Therapeutics, Inc. has entered into an Equity Distribution Agreement to sell up to $8.56 million of common stock through an at-the-market offering.

Summary

• Dogwood Therapeutics, Inc. (the Company) entered into an Equity Distribution Agreement (the Agreement) with Northland Securities, Inc. (Northland Capital Markets) on November 28, 2025.
• The Agreement establishes an at-the-market (ATM) program for the issuance and sale of shares of the Company's common stock, par value $0.0001 per share.
• The aggregate offering price for the shares under the ATM program is up to $8,558,712.
• This amount represents 21.38% of the value of the Company's outstanding common stock held by non-affiliates.
• Sales of shares, if any, will be made from time to time through Northland Securities, Inc. as a sales agent.
• The Company will pay the Sales Agent a commission of 3.0% of the gross offering proceeds from shares sold through the program.
• The shares will be sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-287575), which was declared effective on June 2, 2025, and a prospectus supplement dated November 28, 2025.
• The ATM program will terminate upon the sale of all shares or earlier in accordance with the Agreement's terms.

Sentiment

Score: 7

Explanation: The filing indicates a proactive step by the company to secure a flexible funding mechanism, which is generally positive for long-term stability and growth. While there's potential for dilution, the ability to raise capital efficiently is a strategic advantage.

Positives

• Provides the Company with a flexible and efficient mechanism to raise capital as needed.
• Allows the Company to access public markets for funding without the need for traditional underwritten offerings, which can be more costly and time-consuming.
• The ability to raise up to $8,558,712 provides additional liquidity and financial flexibility for future operations and strategic initiatives.

Negatives

• Potential for dilution of existing shareholders as new shares are issued and sold into the market.
• The continuous nature of at-the-market offerings can exert downward pressure on the stock price.
• There is no assurance that the Sales Agent will be successful in selling all or any of the shares, impacting the Company's ability to raise the full amount.

Risks

• There can be no assurance that the Sales Agent will be successful in selling the Shares under the ATM program.
• The Company has agreed to indemnify the Sales Agent against certain liabilities, including those under the Securities Act, which represents a contingent financial exposure.
• The continuous offering of shares could lead to dilution for current shareholders and potentially impact the market price of the common stock.

Future Outlook

The Company intends to utilize the at-the-market program to raise capital from time to time, providing ongoing financial flexibility for its operations and strategic objectives. The program will continue until all authorized shares are sold or the agreement is terminated.

Industry Context

At-the-market (ATM) offerings are a common and flexible financing tool used by publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to raise capital incrementally. This method allows companies to tap into market demand without the significant upfront costs and market disruption often associated with traditional underwritten offerings. It reflects a strategic approach to managing capital needs in a dynamic market environment.

Comparison to Industry Standards

• ATM programs are a standard financing mechanism across various industries, including biotechnology and healthcare, for companies seeking flexible capital access.
• The commission rate of 3.0% is within the typical range for such agreements, which can vary based on market conditions, company size, and the sales agent's role.
• The maximum offering size of $8.56 million, representing 21.38% of non-affiliate outstanding common stock, is a significant but not uncommon proportion for companies utilizing ATM facilities to manage their capital structure and funding requirements.

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of new common stock, but also benefits from the company's enhanced ability to fund operations and growth.
• Company: Gains a flexible and efficient method to raise capital, supporting ongoing operations and strategic initiatives.

Next Steps

• The Company may, from time to time, submit orders to the Sales Agent to sell shares under the ATM program.
• The Sales Agent will use commercially reasonable efforts to execute sales orders.
• The Company will file quarterly and annual reports detailing sales made through the ATM program.

Key Dates

Keywords

Dogwood Therapeutics, ATM Program, Equity Distribution Agreement, Capital Raise, Common Stock, Nasdaq Capital Market, Dilution, Securities Offering